2023, Disease and Radiopharmaceuticals - Diagnostic Imaging Brief

Italian research team shows the way on sustainability

AuntMinnie

FEBRUARY 26, 2025

It can detect progressive disease in cases missed by other modalities, demonstrating its potential to guide treatment decisions effectively," they noted. The researchers analyzed 78 patients (median age: 57 years, range 32-81 years) who participated in a diagnostic protocol between September 2019 and July 2023.

Bone Scan

Bone Scan Radiopharmaceuticals Imaging Modalities Bone Scintigraphy

Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

Imaging Technology

OCTOBER 17, 2023

milla1cf Tue, 10/17/2023 - 13:07 October 17, 2023 — Radionetics Oncology, Inc., Adrenocortical carcinoma is a disease with a desperate need for new agents, as the last drug approved by the FDA was in 1970. Despite significant research efforts, the median survival of patients with metastatic disease is less than 15 months.

Radiopharmaceuticals

Radiopharmaceuticals Disease Clinic Diagnose

AI helps predict kidney function decline in Lu-177 patients

AuntMinnie

FEBRUARY 24, 2025

An open-source AI tool can help predict renal function decline in prostate cancer patients undergoing lutetium-177 (Lu-177) radiopharmaceutical therapy, according to a study published February 25 in Radiology. In total, 363 CT studies were included, comprising 121 baseline and 242 follow-up scans. The full study is available here.

Radiopharmaceuticals

Radiopharmaceuticals Disease Clinic Radiation

Evidence grows for use of amyloid PET in China

AuntMinnie

FEBRUARY 12, 2024

Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University.

PET Scan

PET Scan Diagnose Disease Radiopharmaceuticals

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 25, 2023

milla1cf Tue, 07/25/2023 - 20:22 July 25, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. FAP is a membrane-bound dipeptidyl peptidase that is specifically expressed in activated fibroblasts.

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 11, 2023

milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. FAP is a membrane-bound dipeptidyl peptidase that is specifically expressed in activated fibroblasts.

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

Will new CPT codes spark utilization of quantitative MRI?

AuntMinnie

JANUARY 30, 2024

The timing of the new codes dovetails with advances in neuroimaging, such as in the assessment of white-matter diseases. FLAIR WMH may have specific risk factors and pathologic underpinnings in [repetitive head impact] RHI-exposed individuals," Alosco's team concluded in their article published in December 2023 in Neurology.

MRI

MRI Radiopharmaceuticals Disease Imaging

Meet the Minnies 2024 finalists

AuntMinnie

OCTOBER 25, 2024

His research interests include using structural and functional MRI -- particularly ultrahigh-field, 7-tesla MRI -- to map brain microstructure and develop neurosurgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia. Elliot Fishman, MD.

Nuclear Medicine

Nuclear Medicine Education Radiology Technologist Radiation Science

GE HealthCare and Axim Life Isotopes South Africa (ALISA) Collaborate to Expand Access to Molecular Imaging in South Africa and Drive Precision Care

Imaging Technology

APRIL 28, 2023

Molecular imaging enables doctors and clinicians to see inside the body with a non-invasive process, helping to diagnose and treat diseases such as cancer, cardiovascular disease , and neurological diseases. It uses biomarkers to highlight molecular changes, which can sometimes alert doctors to possible disease.

Healthcare

Healthcare Healthcare Radiopharmaceuticals PET Scan

World’s First Cancer Patient Treated with RefleXion’s Breakthrough SCINTIX Biology-guided Radiotherapy

Imaging Technology

AUGUST 23, 2023

milla1cf Wed, 08/23/2023 - 19:19 August 23, 2023 — RefleXion Medical , a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX biology-guided radiotherapy on the RefleXion X1 machine at the Stanford Medicine Cancer Center.

Radiopharmaceuticals

Radiopharmaceuticals Disease Radiation Clinic

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Imaging Technology

DECEMBER 6, 2023

milla1cf Wed, 12/06/2023 - 18:20 December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., The first three enrolled patients in the trial were imaged in November 2023 at the National Cancer Institute of Milan (INT). Chief Executive Officer of Blue Earth Diagnostics.

Diagnostic

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals

New Guidance for Amyloid and Tau PET Imaging Released

Imaging Technology

JANUARY 30, 2025

30, 2025 Earlier this month, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Thu, 01/30/2025 - 10:20 Jan.30,

Nuclear Medicine

Nuclear Medicine Imaging Patient Care Disease

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

AUGUST 29, 2023

Alan Taylor , stated, “Large-scale manufacture of therapeutic Cu-67 from highly efficient, environmentally preferable electron accelerators is critical to overcome the widespread supply issues in the radiopharmaceutical industry, due to a heavy reliance on a small number of antiquated nuclear reactors.

Pharmaceutical

Pharmaceutical Radiopharmaceuticals Clinic Medical

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. How many centers have the physical space in their nuclear medicine departments to treat a disease as common as prostate cancer?" However, few freestanding theranostics centers exist today. Morris continued in the JNM.

Nuclear Medicine

Nuclear Medicine Radiation Oncology Nursing Radiation

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

Imaging Technology

JUNE 19, 2023

milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., NorthStar’s commercialized, U.S.-based

Medical

Medical Pharmaceutical Radiopharmaceuticals Nuclear Medicine

PanTera and TerraPower Isotopes Join Forces to Accelerate Access to Actinium-225

Imaging Technology

AUGUST 28, 2023

milla1cf Mon, 08/28/2023 - 13:57 August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that they have signed a strategic collaboration to increase the global availability of actinium-225 (225Ac), a radioisotope that has the potential to treat a large variety of cancer indications.

Radiopharmaceuticals

Radiopharmaceuticals Pharmaceutical Medical Clinic

CMS Assigns Accretive Reimbursement for RefleXion’s Breakthrough SCINTIX Therapy

Imaging Technology

JANUARY 12, 2024

Other technologies use anatomical images to guide radiotherapy delivery; however, SCINTIX therapy is the only radiotherapy to use emissions from cancer cells, created by injecting the patient with a radiopharmaceutical, to deliver a radiation dose that continuously and autonomously targets the cancer itself.

Radiopharmaceuticals

Radiopharmaceuticals Radiation Medicare Clinic

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic

Clinic Nuclear Medicine Radiopharmaceuticals Radiation

iThemba LABS ready to start production of Strontium-82 and Germanium-68 using IBA Cyclone 70

Imaging Technology

JANUARY 23, 2024

Acceptance testing was completed in December 2023, with the cyclotron reaching full beam power (750µA) at full energy. This 70 MeV cyclotron will be dedicated to the production of next-generation medical isotopes used mainly in the diagnosis of critical illnesses.

Radiopharmaceuticals

Radiopharmaceuticals Disease Diagnostic Clinic

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. manufacturer and distributor, PETNET Solutions Inc, A Siemens Healthineers Company.

Diagnostic

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 Gauden , D.Phil.,

Diagnostic

Diagnostic Radiopharmaceuticals Imaging Radiation

Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

Imaging Technology

JUNE 26, 2023

Mahmood was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) at its 2023 Annual Meeting. For more information: www.snmmi.org Find more SNMMI23 conference coverage here Monday, June 26, 2023 - 19:43

Nuclear Medicine

Nuclear Medicine Education Radiopharmaceuticals Hospital

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

SEPTEMBER 27, 2023

from October 1 to 4, 2023. from October 1 to 4, 2023. Details of selected oral and poster presentations by Blue Earth Diagnostics and its collaborators are listed below. HIGHLIGHTED SCIENTIFIC PRESENTATIONS Monday, October 2, 2023 Oral presentation Title: Detection Rate of 18F-rhPSMA-7.3 Gauden , D.Phil.,

Diagnostic

Diagnostic Radiation Oncology Radiation Clinic

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

JULY 28, 2023

Food and Drug Administration (FDA) on May 25, 2023. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. POSLUMA was approved by the U.S. It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.

Diagnostic

Diagnostic Clinic Radiopharmaceuticals Radiation

Dr. Sameer Keole voted President-elect of the American Society for Radiation Oncology (ASTRO)

Imaging Technology

JULY 20, 2023

milla1cf Thu, 07/20/2023 - 20:11 July 20, 2023 — The members of the American Society for Radiation Oncology ( ASTRO ) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole , MD, FASTRO , as President-elect; Wendy Woodward , MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S.

Radiation Oncology

Radiation Oncology Radiation Government Community Practice

MIM Software Receives FDA Clearance for Theranostics Portfolio

Imaging Technology

OCTOBER 4, 2024

As Theranostics and the use of radiopharmaceutical therapy (RPT) to treat cancer and other diseases have become more prevalent, interest in using dosimetry to personalize RPT treatments has grown. Dosimetry in Radiopharmaceutical Therapy. 2023 May 22;68(11). J Nucl Med. 2022 Oct;63(10):1467-1474. doi: 10.2967/jnumed.121.262305.

Radiopharmaceuticals

Radiopharmaceuticals Nuclear Medicine Radiation Healthcare

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

Diagnose

Diagnose Diagnostic Disease Radiation

Meet the Minnies 2024 semifinal candidates

AuntMinnie

OCTOBER 2, 2024

Ultrasound model predicts liver disease progression. Horowitz, et al, Medical Hypotheses , October 13, 2023. Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion. Plesner, et al, Radiology , September 26, 2023. SPECT/CT reveals heart’s response to tafamidis.

Digital Imaging and Communications in Medicine

Digital Imaging and Communications in Medicine X-ray MRI Hospital

Unlocking the potential of imaging in Alzheimer’s disease care

AuntMinnie

JANUARY 19, 2024

more than 6 million Americans have Alzheimer's disease, a debilitating and far-reaching disease that accounts for 60% to 80% of dementia cases, and by 2050, this number is projected to rise to nearly 13 million, according to Alzheimer’s Disease International. The disease affects memory, thinking, and behavior. In the U.S.,

Disease

Disease Imaging Medicare PET Scan

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 for use in radiopharmaceutical therapy (RPT).

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

Widespread Staff Shortages Exacerbate Pressures Facing Radiation Oncology Clinics; ASTRO Advocacy Day Calls for Action

Imaging Technology

MAY 23, 2023

milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for Radiation Oncology ( ASTRO ). in the past three decades.

Radiation Oncology

Radiation Oncology Radiation Clinic Medicare

New criteria released for amyloid and tau PET imaging

AuntMinnie

JANUARY 8, 2025

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association have released new appropriate use criteria for brain PET imaging of amyloid and tau pathology related to cognitive impairment and Alzheimers disease. Since then, the U.S. There are three PET radiotracers labeled with F-18 approved by the U.S.

Nuclear Medicine

Nuclear Medicine Imaging Radiopharmaceuticals Medicare

Updated Appropriate Use Criteria for Amyloid and Tau PET Imaging Released

Imaging Technology

JANUARY 14, 2025

8, 2025 The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association have released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Tue, 01/14/2025 - 16:48 Jan.8,

Nuclear Medicine

Nuclear Medicine Imaging Patient Care PET Scan

Diagnostic Imaging Brief

Italian research team shows the way on sustainability

Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

Trending Sources

AI helps predict kidney function decline in Lu-177 patients

Evidence grows for use of amyloid PET in China

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

The rise of theranostics: Part 1 -- Gaining momentum

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Will new CPT codes spark utilization of quantitative MRI?

Meet the Minnies 2024 finalists

GE HealthCare and Axim Life Isotopes South Africa (ALISA) Collaborate to Expand Access to Molecular Imaging in South Africa and Drive Precision Care

World’s First Cancer Patient Treated with RefleXion’s Breakthrough SCINTIX Biology-guided Radiotherapy

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

New Guidance for Amyloid and Tau PET Imaging Released

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

The rise of theranostics: Part 2 -- Moving into communities

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

PanTera and TerraPower Isotopes Join Forces to Accelerate Access to Actinium-225

CMS Assigns Accretive Reimbursement for RefleXion’s Breakthrough SCINTIX Therapy

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

iThemba LABS ready to start production of Strontium-82 and Germanium-68 using IBA Cyclone 70

The rise of theranostics: Part 1 -- Gaining momentum

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Dr. Sameer Keole voted President-elect of the American Society for Radiation Oncology (ASTRO)

MIM Software Receives FDA Clearance for Theranostics Portfolio

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Meet the Minnies 2024 semifinal candidates

Unlocking the potential of imaging in Alzheimer’s disease care

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

Widespread Staff Shortages Exacerbate Pressures Facing Radiation Oncology Clinics; ASTRO Advocacy Day Calls for Action

New criteria released for amyloid and tau PET imaging

Updated Appropriate Use Criteria for Amyloid and Tau PET Imaging Released

Stay Connected